Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Liver Neoplasms 3Stomach Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Solid Malignancies 1Seminoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Non Small Cell Lung Cancer NSCLC 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Metastatic Malignant Female Reproductive System Neoplasm 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Immunotherapy 1Hydronephrosis 1

Interventions

Paclitaxel 3Cytoreduction Surgical Procedures 2tremelimumab 1soluble LAG-3 protein, human 1sodium thiosulfate 1relacorilant 1oregovomab 1olaparib 1avelumab 1Taxes 1Observation 1Leucovorin 1Hyperthermic Intraperitoneal Chemotherapy 1Fluorouracil 1Cisplatin 1Cell Count 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Peritoneal Neoplasms × tremelimumab × Clear all
NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

New Mexico Cancer Research Alliance

Phase 1/2 Active not recruiting
50 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡